Industry News

Impax Laboratories, Inc., a specialty pharmaceutical company, today reported second quarter 2016 financial results for the quarter ended June 30, 2016.. Total revenues in the second quarter 2016 declined 19% to $172.6 million, compared to $214.2 million in the prior year period. The decrease was primarily due to a 30% reduction in Generics division revenues which includes the impact of an approximate $15.0 million shelf-stock adjustment..."/>
Impax Reports Second Quarter 2016 Financial Results
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced that its critical limb ischemia program in the European Union has been awarded an $8 million grant. The grant is part of the..."/>
Pluristem’s Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe’s Horizon 2020 Program
Alliqua BioMedical, Inc., a provider of advanced wound care products, today announced financial results for the second quarter ended June 30, 2016.. Second Quarter 2016 Financial Summary:. Total revenue of $5.5 million, up 75% year-over-year, compared to revenue of $3.1 million in the second quarter of 2015."/>
Alliqua BioMedical, Inc. Reports Second Quarter and Six Months Fiscal Year 2016 Financial Results
Concert Pharmaceuticals, Inc. today reported financial results for the second quarter of 2016.. “Concert has made significant progress with our pipeline of multiple products, including CTP-656 and CTP-543, both of which we are committed to advancing into efficacy trials in 2017."/>
Concert Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Company Update
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the third quarter ended..."/>
GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress
Ionis Pharmaceuticals, Inc. today reported that its financial results for the first half of 2016 were in line with the Company's expectations and the Company is on track to meet its pro forma NOL and cash guidance for the year. "The recent announcement to file for regulatory approval of nusinersen based on positive results from an interim analysis of the Phase 3 ENDEAR study was an important next step in our goal to bring this potentially..."/>
Ionis Pharmaceuticals Reports Financial Results and Highlights for Second Quarter 2016
Eagle Pharmaceuticals, Inc. today announced its financial results for the three- and six-months ended June 30, 2016. Highlights of and subsequent to the second quarter of 2016 include:."/>
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results
Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, today reported financial results for the second quarter ended June 30, 2016 and provided a business update. “This quarter, we made important progress on our development plans across our clinical pipeline,” stated Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics.“ As planned, in June we enrolled our first patient in our Phase 3 INOvation-1..."/>
Bellerophon Reports Second Quarter 2016 Financial Results and Provides Business Update
Accuray Incorporated announced today that it has CE marked its Radixact™ Treatment Delivery System, Accuray Precision™ Treatment Planning System and iDMS™ Data Management System. The next generation hardware and software solutions, together, make up the new Radixact platform, which represents a major step forward in the evolution of Accuray's existing TomoTherapy ® System in treatment speed and ease of use. The platform will now be..."/>
Accuray CE Marks its New Radixact™ System
Vical Incorporated today reported financial results for the three and six months ended June 30, 2016. Net loss for the second quarter of 2016 was $1.3 million, or $0.14 per share, compared with a net loss of $2.8 million, or $0.30 per share, for the second quarter of 2015. Revenues for the second quarter of 2016 were $4.1 million, compared with revenues of $4.2 million for the second quarter of 2015, reflecting revenues from Astellas Pharma Inc. for manufacturing..."/>
Vical Reports Second Quarter 2016 Financial Results
ProMetic Life Sciences Inc. announced today that it has completed the enrolment of the adult patient population in its pivotal IVIG phase III clinical trial for the treatment of primary immunodeficiency diseases. The ongoing pivotal Phase III clinical trial is an..."/>
ProMetic Completes Adult Patients' Enrolment in Pivotal IVIG Phase 3 Clinical Trial
Cellular Biomedicine Group Inc., a clinical-stage biomedicine firm engaged in the development of immunotherapies for cancer and effective stem cell therapies for degenerative diseases, today reported financial results and business highlights for the second quarter and six months ended June 30, 2016.. “In the first half of 2016, we made several significant advancements..."/>
Cellular Biomedicine Group Reports Second Quarter and First Half 2016 Financial Results and Business Highlights
Moberg Pharma AB reported on Tuesday that its net profit after tax was SEK28.0m, or EPS of SEK1.96, for the second quarter of 2016, from April 2016 to June 2016.. This was in comparison with net profit after tax of SEK5.5m, or EPS of SEK0.38, in Q2 of 2015.. Revenues for the second quarter were SEK71.3m, as compared with SEK92.2m in Q2 2015.."/>
Moberg Pharma posts net profit of SEK28.0m in Q2 2016
Moberg Pharma AB reported on Tuesday that its net profit after tax was SEK28.0m, or EPS of SEK1.96, for the second quarter of 2016, from April 2016 to June 2016.. This was in comparison with net profit after tax of SEK5.5m, or EPS of SEK0.38, in Q2 of 2015.. Revenues for the second quarter were SEK71.3m, as compared with SEK92.2m in Q2 2015.."/>
Moberg Pharma posts net profit of SEK28.0m in Q2 2016
Achillion Pharmaceuticals, Inc. announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 10:55am EDT at the Le Parker Meridien Hotel in New York City, NY.. The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations..."/>
Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference
BioDelivery Sciences International, Inc. today reported financial results for the second quarter ended June 30, 2016, and provided an update on recent business highlights and upcoming milestones. BDSI's total net revenue for the three-months ended June 30, 2016, was $5.0 million, an increase of 65% over the first quarter of 2016 and an increase of 189% over last year's corresponding quarter. BUNAVAIL buccal film net revenue for the three..."/>
BioDelivery Sciences Provides Corporate Update and Reports Second Quarter 2016 Financial Results

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary542 Articles
Information Technology507 Articles
Financials386 Articles
Industrials296 Articles
Health Care295 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.